Search hospitals > Connecticut > Orange
Smilow Cancer Hospital-Orange Care Center
Claim this profileOrange, Connecticut 06477
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
100 reported clinical trials
29 medical researchers
Summary
Smilow Cancer Hospital-Orange Care Center is a medical facility located in Orange, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Smilow Cancer Hospital-Orange Care Center is involved with conducting 100 clinical trials across 174 conditions. There are 29 research doctors associated with this hospital, such as Joseph W. Kim, MD, Jeremy S. Kortmansky, Debra S. Brandt, and Hari A. Deshpande.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Joseph W. Kim, MDYale University8 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
12 reported clinical trials
25 drugs studied
Jeremy S. KortmanskyYale University6 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
6 reported clinical trials
18 drugs studied
Debra S. BrandtJupiter Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
8 reported clinical trials
19 drugs studied
Hari A. DeshpandeYale University7 years of reported clinical research
Studies Hemangiosarcoma
Studies Leiomyosarcoma
5 reported clinical trials
11 drugs studied
Clinical Trials running at Smilow Cancer Hospital-Orange Care Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Prostate Cancer
Multiple Myeloma
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors
Cancer
Ovarian Cancer
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
DiviTum-TKa Assay
for Breast Cancer
This clinical trial assesses whether using a test developed by DiviTum can identify optimal levels of CDK 4/6 inhibitor medications in the blood and whether assessing medical compliance and drug-drug interactions can optimize (improve) these levels in patients with estrogen receptor (ER) or progesterone receptor (PR) positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and are receiving CDK 4/6 inhibitors. CDK4/6 inhibitors in combination with endocrine therapy (ET) is first line treatment for metastatic hormone positive (ER/PR positive) breast cancer (mBC). Thymidine kinase is a biomarker (biological molecule found in blood, other body fluids, or tissues that is a sign of a condition or disease) that reflects cell proliferation (an increase in the number of cells as a result of cell growth and cell division). DiviTum-thymidine kinase activity (TKa) is a Food and Drug Administration approved assay which showed that a TKa is associated with the decreased likelihood of disease progression within 30 days or 60 days post testing. Using the DiviTum-TKa may improve medication compliance and remove potential drug-drug interactions in patients with ER/PR positive HER2-negative MBC.
Recruiting1 award N/A5 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Smilow Cancer Hospital-Orange Care Center?
Smilow Cancer Hospital-Orange Care Center is a medical facility located in Orange, Connecticut. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Smilow Cancer Hospital-Orange Care Center is involved with conducting 100 clinical trials across 174 conditions. There are 29 research doctors associated with this hospital, such as Joseph W. Kim, MD, Jeremy S. Kortmansky, Debra S. Brandt, and Hari A. Deshpande.